Holen Sie sich die Stockscreener-App
32.56
3.46%
1.09
Schlusskurs vom Vortag:
$31.47
Offen:
$31.45
24-Stunden-Volumen:
5.86M
Relative Volume:
1.45
Marktkapitalisierung:
$5.30B
Einnahmen:
$56.99M
Nettoeinkommen (Verlust:
$-107.23M
KGV:
-39.71
EPS:
-0.8199
Netto-Cashflow:
$-142.55M
1W Leistung:
+14.25%
1M Leistung:
+48.13%
6M Leistung:
+272.11%
1J Leistung:
+549.90%
1-Tages-Spanne:
$31.03
$32.70
1-Wochen-Bereich:
$28.01
$32.70
52-Wochen-Spanne:
$4.80
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
32.56 | 5.12B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
TNGX Upgraded by Jefferies -- Price Target Raised to $60 - GuruFocus
Tango Therapeutics Inc (TNGX) Institutional Confidence - TradingKey
Tango Therapeutics, Inc. Actuals & Estimates (NASDAQ:TNGX) - TradingView
Enterprise value to EBIT forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60 - Moomoo
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data By Investing.com - Investing.com India
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data - Investing.com
TNGX Forecast — Price Target — Prediction for 2027 - TradingView
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
Price to sales forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Form 8K Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 4 Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
Director at Tango Therapeutics (TNGX) receives RSUs and stock options - Stock Titan
New Tango Therapeutics (TNGX) director Robert Azelby files initial Form 3 - Stock Titan
Robert Azelby appointed to Tango Therapeutics board, joins Compensation and NCG Committees - TradingView
Biotech veteran Robert Azelby joins Tango Therapeutics (TNGX) board as company advances vopimetostat - Stock Titan
Positive trial data lifts forecasts for Tango Therapeutics’ oncology program - S&P Global
Tango Therapeutics Appoints New Board Member - Intellectia AI
Tango Therapeutics Inc (TNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tango Therapeutics Company Profile & Introduction - Moomoo
Tango Therapeutics appoints Robert Azelby to board of directors By Investing.com - Investing.com South Africa
Tango Therapeutics appoints Robert Azelby to board of directors - Investing.com
Tango Therapeutics Appoints Robert Azelby to Board of Directors - The Manila Times
Press Release: Tango Therapeutics Appoints Robert Azelby to Board of Directors - Moomoo
Tango Therapeutics files for $500 million common stock offering - MSN
ACUTA CAPITAL PARTNERS, LLC's Tango Therapeutics Inc(TNGX) Holding History - GuruFocus
Tango Therapeutics Inc (TNGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tango Therapeutics stock hits all-time high at 33.19 USD By Investing.com - Investing.com Australia
TNGX (Nasdaq: TNGX) affiliate files Form 144 to sell 3.5M shares - Stock Titan
Tango Therapeutics stock hits all-time high at 33.19 USD - Investing.com
Tango Therapeutics Inc (TNGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tango Therapeutics Inc (TNGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):